hat
Dènye etid yo endike ke stenabolic se yon ajan anti-kansè. Antagonist kansè SR9009 afekte chofè onkogenic, ki gen ladan PIK3CA, HRAS, ak BRAF. Nan selil malfezan yo, pwodwi a antrenè apoptoz ak afekte kwasans nan timè san yo pa sa ki lakòz efè negatif.
eng
Recent studies indicate that stenabolic is an anti-cancer agent. SR9009 cancer antagonist affects oncogenic drivers, including PIK3CA, HRAS, and BRAF. In malignant cells, the product induces apoptosis and impairs tumor growth without causing adverse effects.